AELIX Therapeutics featured as a case study for EFSI

How EFSI (European Fond for Strategic Investments) benefits SMEs in Europe - Ysios Biofund II Innvierte case study: AELIX (Spain), Life Sciences
By Vesna | January 16, 2018
How EFSI (European Fond for Strategic Investments) benefits SMEs in Europe – Ysios Biofund II Innvierte case study: AELIX (Spain), Life Sciences

AELIX Therapeutics is a drug development company specialized in the development of a therapeutic vaccine (not to be confused with preventive vaccines) that will be used in cure and eradication strategies against HIV infection. “The vaccine will re-educate the immune system of patients so that they can control their HIV infection without further antiretroviral therapy” explains Jordi Naval, co-founder and Director at AELIX.

Read more: http://www.eif.org/what_we_do/equity/Case_studies/efsi_innovfin_aelix_spain.htm